RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kiadis Pharma Stock

Kiadis Pharma Employees 2024

Kiadis Pharma Employees

0

Ticker

KDS.AS

ISIN

NL0011323407

WKN

A14VE3

In 2024, Kiadis Pharma employed 0 people, a 0% change from the 0 number of employees in the previous year.

Kiadis Pharma Aktienanalyse

What does Kiadis Pharma do?

Kiadis Pharma NV was founded in 1997 in Amsterdam and is an innovative biotechnology company specializing in the development of cell therapies for the treatment of blood cancer diseases. The company is based in the Netherlands and is listed on the Euronext Amsterdam stock exchange. The business model of Kiadis is based on the development of therapies for patients with high medical needs, especially for individuals with severe blood cancer diseases for which there are no cure options. The company employs a proprietary platform technology that is based on the activation of T-cells for the therapy of cancer patients. Kiadis is currently developing various therapeutic approaches for the treatment of blood cancer diseases such as leukemia, lymphoma, and multiple myeloma. The company's main products are ATIR101 and ATIR201. ATIR101 is a cell therapy for patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) who require an allogeneic stem cell transplant. This therapy aims to reduce the risk of transplant rejection and graft-versus-host disease (GVHD), thereby increasing patients' chances of survival. ATIR201 is a therapy for the treatment of patients with multiple myeloma who require an allogeneic stem cell transplant. This therapy aims to reduce the risks of transplant rejection and GVHD, thereby increasing patients' chances of survival. Kiadis has also developed another platform technology called CytoSen, which is based on the activation of NK cells for the immunotherapy of cancer. The CytoSen technology aims to enhance the effectiveness of T-cell therapy by combining it with NK cells. Kiadis is continuously working to improve and expand its products and therapies. The company has a strong pipeline of product candidates at various stages of development targeting the treatment of leukemia, lymphoma, multiple myeloma, and other cancer diseases. The company has also entered into a partnership with Sanofi to accelerate the development of its therapies. Overall, Kiadis Pharma NV has an impressive history as an innovative company with a clear focus on the development of cell therapies for the treatment of blood cancer diseases. The company is dedicated to improving the lives of cancer patients and continuously works on the development of new therapies to improve the chances of survival and quality of life for cancer patients worldwide. Kiadis Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Kiadis Pharma's Employee Base

Kiadis Pharma's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Kiadis Pharma's operational capacity and future potential.

Year-to-Year Comparison

Assessing Kiadis Pharma's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Kiadis Pharma's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Kiadis Pharma’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Kiadis Pharma stock

How many employees does Kiadis Pharma have this year?

Kiadis Pharma has 0 undefined employees this year.

How many employees did Kiadis Pharma have compared to the previous year?

Compared to the previous year, Kiadis Pharma had 0% more employees.

What impact did the number of employees have on the company Kiadis Pharma?

The number of employees has a direct impact on the efficiency and productivity of Kiadis Pharma. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Kiadis Pharma?

The number of employees can also have an impact on investors of Kiadis Pharma, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Kiadis Pharma affect the company?

An increase in equity of Kiadis Pharma can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Kiadis Pharma's equity affect the company?

A reduction in equity of Kiadis Pharma can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Kiadis Pharma?

Some factors that can influence the equity of Kiadis Pharma include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Kiadis Pharma so important for investors?

The equity of Kiadis Pharma is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Kiadis Pharma influence the company?

The number of employees at Kiadis Pharma can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Kiadis Pharma evolved in recent years?

In recent years, the number of employees at Kiadis Pharma has changed by NaN.

How many employees does Kiadis Pharma currently have?

Kiadis Pharma currently has 0 undefined employees.

Why is the number of employees important for investors of Kiadis Pharma?

The number of employees is important for investors of Kiadis Pharma as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Kiadis Pharma take to change the number of employees?

To change the number of employees, Kiadis Pharma can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Kiadis Pharma pay?

Over the past 12 months, Kiadis Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kiadis Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Kiadis Pharma?

The current dividend yield of Kiadis Pharma is .

When does Kiadis Pharma pay dividends?

Kiadis Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kiadis Pharma?

Kiadis Pharma paid dividends every year for the past 0 years.

What is the dividend of Kiadis Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kiadis Pharma located?

Kiadis Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kiadis Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kiadis Pharma from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Kiadis Pharma pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Kiadis Pharma in the year 2023?

In the year 2023, Kiadis Pharma distributed 0 EUR as dividends.

In which currency does Kiadis Pharma pay out the dividend?

The dividends of Kiadis Pharma are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Kiadis Pharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Kiadis Pharma

Our stock analysis for Kiadis Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kiadis Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.